Effectiveness of mRNA booster doses against the omicron variant
| Author | Hadeel T, Zedan |
| Author | Nasrallah, Gheyath K |
| Available date | 2022-08-25T06:29:35Z |
| Publication Date | 2022-09-30 |
| Publication Name | The Lancet Infectious Diseases |
| Identifier | http://dx.doi.org/10.1016/S1473-3099(22)00319-X |
| ISSN | 14733099 |
| Abstract | Since its emergence in November, 2021, the omicron (B.1.1.529) variant of SARS-CoV-2 has rapidly spread and quickly overtaken the delta (B.1.617.2) variant as the most common cause of infection.1 Due to numerous spike mutations, the omicron variant showed increased transmissibility and reduced neutralisation by antibodies from prior infections compared with the wild-type virus and other variants of concern. Concurrently, breakthrough infections surged in populations with high vaccination rates, which expedited efforts to scale up booster vaccination. |
| Language | en |
| Publisher | Elsevier |
| Subject | mRNA omicron |
| Type | Other |
| Issue Number | 9 |
| Volume Number | 22 |
Check access options
Files in this item
This item appears in the following Collection(s)
-
Biomedical Research Center Research [666 items ]
-
Biomedical Sciences [646 items ]
-
COVID-19 Research [755 items ]